AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03106922 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Klean-prep
Description: Powder for oral solution:~macrogol 3350 59.000 g, anhydrous sodium sulphate 5.685 g, sodium bicarbonate 1.685 g, sodium chloride 1.465 g, potassium chloride 0.7425 g.~One sachet to be dissolved in 1 L of water
Study NCT01238146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine hydrochloride
Description: Given IV
Study NCT01238146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: obatoclax mesylate
Description: Given IV
Study NCT01238146 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study NCT00790413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iodine I 131 metaiodobenzylguanidine
Study NCT02584452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Intraoperative opioid should be limited to no more than 150mcg of fentanyl.
Study NCT02021890 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dance program
Description: two-hour dancing session twice a week, led by instructors in a private hall of a disco. Both solo and partner and group dances were performed during each session: an initial one-hour activity, chaired by two instructors who taught new steps and choreographies to patients (both individually and in group), was followed by a second hour, when patients danced in pairs both Latin and standard ballroom music
Study NCT02021890 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-selected physical activity
Description: gym sessions (with the support of sports associations), exercising at home (cycling, stepping) or walking, jogging or cycling outside with/without group support
Study NCT00566007 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Discectomy/ micro discectomy
Description: Standard discectomy or micro discectomy
Study NCT00566007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ozone therapy
Description: Infiltration of intradiscal ozone: O3/O2 in a 27 micrograms/ml concentration + foraminal infiltration of O3/O2 + corticoid + anesthetic
Study NCT00566007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen therapy
Description: Intradiscal oxygen therapy: O3/O2 at a concentration of 0 micrograms/ml (only oxygen) + foraminal infiltration of O2 + corticoid + anesthetic
Study NCT02167373 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cogito Companion Intervention
Study NCT02167373 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mobile phone application
Study NCT02820649 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sleep deprivation
Description: 40 hours of continuous wakefullness
Study NCT02820649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Description: 40 hours of continuous wakefullness
Study NCT02098239 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G17DT
Study NCT01172119 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biofreedom Drug Eluting Stent
Description: Biofreedom DES with a standard dose of Biolimus A9TM
Study NCT01172119 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biofreedom Drug Eluting Stent
Description: Biofreedom DES with a low dose of Biolimus A9TM
Study NCT01172119 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tuxus Liberte Drug Eluting Stent
Description: Standard paclitaxel dose Taxus Liberte DES
Study NCT04510051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT04510051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study NCT04510051 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes
Description: Given intraventricularly
Study NCT04338204 — intervention group
Intervention type: DRUG
Intervention: tofacitinib
Description: Observational study
Study NCT01023685 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAD106
Study NCT00790413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Study NCT00790413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Study NCT00790413 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: T-cell depletion
Study NCT00790413 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Haploidentical stem cell transplantation
Study NCT00790413 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Donor Lymphocyte Infusion
Study NCT02647203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Self-administered fluoridated dentifrices
Description: Elderly participants will be instructed to self administer toothpastes, twice per day. Toothpastes will be provided.
Study NCT00732017 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard physical therapy and HVPC with positive polarity
Description: A high voltage stimulator with positive polarity was used with a direct pulsed monophasic current, double peak, 5 and 8micros duration and separated by a pulsate interval of 75micros and monopolar application with a dispersive electrode in the lumbar region and two transarticular active electrodes. The intensity of the current was under motor level, that is, just before a visible motor response could be observed. The frequency used was 120pps, in a continuous mode and was applied once a day with thirty-minute duration.
Study NCT00732017 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high voltage pulse stimulation with negative polarity
Description: A high voltage stimulator with negative polarity was used with a direct pulsed monophasic current, double peak, 5 and 8micros duration and separated by a pulsate interval of 75micros and monopolar application with a dispersive electrode in the lumbar region and two transarticular active electrodes. The intensity of the current was under motor level, that is, just before a visible motor response could be observed. The frequency used was 120pps, in a continuous mode and was applied once a day with thirty-minute duration.
Study NCT00732017 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard physical therapy treatment
Description: * Initial phase: Application of crushed ice on the ankle for 20 minutes. The subject performed isometric and active exercises of the ankle in all freedom degrees, with no weight bearing.~* Intermediate phase: Application of cryotherapy continued and once mobility was completed and painless, progressive use of weight and reeducation of the walking pattern were initiated. Then, exercises with manual resistance of muscles of ankle and balance in stable surfaces were done.~* Advanced phase: Balance exercises on unstable surfaces as well as strengthening ankle muscles with proprioceptive neuromuscular facilitation techniques and elastic band were performed. At the end, the patient did activities like trotting in S or Z and jumping in all directions.
Study NCT02034110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: A 150 mg twice daily capsule administered orally on a continuous basis.
Study NCT02034110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: A 2 mg once daily tablet administered orally on a continuous basis.
Study NCT03736616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Chemotherapy
Study NCT03736616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Chemotherapy
Study NCT03736616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Chemotherapy
Study NCT03736616 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Anti-CD20 mAb
Study NCT00790413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Study NCT00790413 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Co-transplantation of mesenchymal stem cells
Study NCT03833440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab (MEDI4736)
Description: 1500 mg, every 4 weeks. CxD1 for each cycle, 1 cycle = 28 days~EXCEPT FOR CYCLE 1 IN ARM C : at C1D8 and cycle 1 = 35 days~c=cycle D= day
Study NCT03357328 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard light
Description: See group description
Study NCT00912496 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF-59
Description: Doses of A/Anhui/05 vaccine (A) will be administered with or without MF59 adjuvant.
Study NCT00912496 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/Anhui/05
Description: Monovalent inactivated surface antigen influenza A/H5N1 (modified Hemagglutinin and Neuraminidase of A/Anhui/01/2005) vaccine supplied in 5mL multi-dose vials with thimerosal \[0.01%(w/v)\] as a preservative. Each dose level includes both unadjuvanted and MF59C.1 adjuvanted formulations: 7.5, 15, 30, or 60 micrograms (mcg) of H5 Hemagglutinin per milliliter (mL) with MF59C.1, and 7.5, 15, 30, or 60 micrograms (mcg) of H5 Hemagglutinin per milliliter (mL) without MF59C.1 adjuvant.
Study NCT03736616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Chemotherapy
Study NCT03736616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Chemotherapy
Study NCT03736616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Chemotherapy
Study NCT03736616 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous HSCT
Description: Cellular Therapy
Study NCT03736616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Bruton's Tyrosine Kinase Inhibitor
Study NCT02720991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: 200 mg of oral mifepristone
Study NCT02720991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol
Description: 400 ug of misoprostol sublingually following mifepristone
Study NCT01180946 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ergocalciferol
Description: ergocalciferol (a dietary form of vitamin D). 50,000 units by mouth once a week for 16 weeks.
Study NCT01180946 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo pill
Description: placebo pill once weekly for 16 weeks. At the end of the study, subjects in this arm will receive vitamin D repletion
Study NCT02223091 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consultation by a trained physician
Study NCT02223091 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Consultation by an untrained physician
Study NCT00666627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibandronate
Description: once monthly
Study NCT00666627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risedronate
Description: Risedronate 35mg once weekly
Study NCT00666627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate
Description: Alendronate 70mg once weekly
Study NCT02466178 — intervention group
Intervention type: DEVICE
Intervention: Serene RF System
Description: The Serene RF System provides percutaneous delivery of radiofrequency (RF) energy to a targeted nerve.
Study NCT00630981 — intervention group
Intervention type: BEHAVIORAL
Intervention: Psychotherapy
Description: Specific psychotherapy for dissociative disorders
Study NCT00630981 — intervention group
Intervention type: DRUG
Intervention: Pharmacological treatment (Quetiapine and/or Escitalopram)
Description: Quetiapine for psychotic symptoms/Escitalopram if depressive disorders
Study NCT00279591 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous blood pressure monitoring using (Dinamap) standard oscillometric blood pressure device
Description: Continuous blood pressure monitoring of patients during med flight to hospital
Study NCT00279591 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care blood pressure monitoring
Description: Patients received the standard of care for blood pressure monitoring while en route to the hospital via med flight.
Study NCT03797599 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 20 minutes of mindfulness practice
Description: A 20 minute audio guided mindfulness of breathing practice per session, for four sessions.
Study NCT03797599 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 5 minutes of mindfulness practice
Description: A 5 minute audio guided mindfulness of breathing practice per session, for four sessions.
Study NCT00678886 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: otelixizumab infusion plus physician determined standard of care
Description: infusion
Study NCT00678886 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo infusion plus physician determined standard of care
Description: infusion
Study NCT03797599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5 minute audio book
Description: 5 minutes from an audio book by Bill Bryson ('A Short History of Nearly Everything') per session, for four sessions.
Study NCT03797599 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 20 minute audio book
Description: 20 minutes from an audio book by Bill Bryson ('A Short History of Nearly Everything'), per session, for four sessions.
Study NCT03797599 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 25 minute audio book
Description: 25 minutes from an audio book by Bill Bryson ('A Short History of Nearly Everything'), per session, for four sessions.
Study NCT01236599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polyethylene for thermoregulation in the preterm infant
Description: 3 groups with 30 preterm infants (PI) each one: 1) PI under radiant warmer, drying, wrapped in sterile field preheated (traditional care), 2) PI under radiant warmer, wrapped in polyethylene bag after drying, with their naked face and access to umbilical catheters or venous access, and 3) PI under radiant warmer, without drying, wrapped in polyethylene bag, with their naked face and access to umbilical catheters or venous access. Body temperature (BT) and incubator temperature (IT) were measured every 15 minutes from birth until 120 minutes of extra uterine life.
Study NCT01236599 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Polyethylene for thermoregulation in the preterm infant
Description: 3 groups with 30 preterm infants (PI) each one: 1) PI under radiant warmer, drying, wrapped in sterile field preheated (traditional care), 2) PI under radiant warmer, wrapped in polyethylene bag after drying, with their naked face and access to umbilical catheters or venous access, and 3) PI under radiant warmer, without drying, wrapped in polyethylene bag, with their naked face and access to umbilical catheters or venous access. Body temperature (BT) and incubator temperature (IT) were measured every 15 minutes from birth until 120 minutes of extra uterine life.
Study NCT03751488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03010
Description: Single Dose of LY03010 at 351 mg or 156 mg or 117mg
Study NCT03751488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Invega Sustenna 156 MG in 1 ML Prefilled Syringe
Description: Single Dose at 156mg
Study NCT01286298 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser gingivectomy
Description: Gingivectomy by diode laser
Study NCT01286298 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser gingivectomy
Description: Diode laser gingivectomy for gingival enlargement
Study NCT00691015 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study NCT00912496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sterile normal saline for injection (0.9% Sodium Chloride Injection, USP Preservative-Free).
Study NCT03833440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monalizumab (IPH2201)
Description: 1500 mg, every 4 weeks. CXD1 for each cycle, 1 cycle = 28 days~c=cycle D= day
Study NCT03833440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleclumab (MEDI9447)
Description: 3000 mg every 2 week x 4 doses, followed by 3000 mg every 4 weeks. C1D1, C1D15, C2D1, C2D15 and CXD1 for the orther cycles, 1 cycle = 28 days.~c=cycle D= day
Study NCT00691015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Given IV
Study NCT00691015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Description: Given IV
Study NCT00691015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00691015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study NCT00691015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT00691015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV
Study NCT00691015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV
Study NCT00691015 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total body irradiation (TBI)
Description: Given once or twice daily
Study NCT00691015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin IV
Description: Given IV
Study NCT00646009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol
Study NCT00646009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone/salmeterol
Study NCT00646009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albuterol
Study NCT04673162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone, Placebo
Description: iv administration
Study NCT04673162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone, Placebo
Description: iv administration
Study NCT02161367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simethicone
Description: Pharmacological category: antiflatulent~160mg Simethicone orally, 4 times a day for the first five postoperative days
Study NCT02161367 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Suspending Vehicle
Description: ORA-Plus is an aqueous-based vehicle.~Identical to the test drug formulation except for being pharmacologically inert. 160mg Ora-Plus orally, 4 times a day for the first five postoperative days
Study NCT02381288 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-448
Description: TAK-448 solution for subcutaneous injection
Study NCT02381288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-448
Description: TAK-448 solution for subcutaneous injection
Study NCT02381288 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-448 Placebo
Description: TAK-448 placebo-matching solution for subcutaneous injection
Study NCT03940404 — intervention group
Intervention type: DRUG
Intervention: Anlotinib Hydrochloride
Description: Anlotinib will give orally, once daily on days 1-14 of a 21-day cycle. Dose reduction is allowed.
Study NCT00869674 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GeneSearch™ Breast Lymph Node (BLN) Assay
Description: Each of the sentinal lymph node will be divided in half according to cutting scheme.~Half of the sentinal lymph node will be tested using rountine pathological method as normal practice, half of the node will have GeneSearch BLN testing.
Study NCT02139228 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hib-CRM197
Description: No vaccine administered in V37_07E2 study
Study NCT02139228 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hib-TT
Description: No vaccine administered in V37_07E2 study
Study NCT02726204 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gravity Elimination Alone
Description: CAREX will compensate for the gravity of the subject's arm, i.e. subject can move their arm to a specific position and relax all the arm muscles, CAREX will hold the arm in that configuration
Study NCT05182138 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Unfortified potato plus placebo
Description: Volunteers will be given 300g of zinc unfortified cooked potato as well as a placebo every day.
Study NCT05182138 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Zinc Biofortified potato plus placebo
Description: Volunteers will be given 300g of cooked potato biofortified with zinc and a placebo every day.
Study NCT05182138 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Unfortified potato plus zinc supplement
Description: Volunteers will be given 300g of zinc unfortified cooked potato and a zinc supplement containing 18mg of zinc, every day.
Study NCT03269383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Patients will receive a stellate ganglion block using 10 ml of 0.5% bupivacaine
Study NCT03269383 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: Patients will receive a stellate ganglion block using 10 ml of 0.9% saline
Study NCT04512404 — intervention group
Intervention type: DRUG
Intervention: HMG-CoA Reductase Inhibitor